Zeekr Group Announces Completion of Merger
HANGZHOU, China, Dec. 22, 2025 /PRNewswire/ -- ZEEKR Intelligent Technology Holding Limited ("Zeekr Group" or the "Company") (NYSE: ZK), the world's leading premium new energy vehicle group, today announced the completion of its merger (the...
Bright Scholar Announces Completion of Going Private Transaction
CAMBRIDGE, England and FOSHAN, China, Dec. 16, 2025 /PRNewswire/ -- Bright Scholar Education Holdings Limited ("Bright Scholar" or the "Company") (NYSE: BEDU), a global premier education service company, today announced the completion of the merger...
Emeren Group Announces Completion of Merger
NORWALK, Conn., Dec. 15, 2025 /PRNewswire/ -- Emeren Group Ltd ("Emeren" or the "Company") (www.emeren.com) (NYSE: SOL), a leading global solar project developer, owner, and operator, today announced the completion of the merger contemplated by the...
State Grid Jinchang (Gansu): Realizing Direct Grid Supply to All Residential Communities
JINCHANG, China, Nov. 27, 2025 /PRNewswire/ -- On November 18, with the completion of power supply renovation for the last 521 households in Phase II of Yongdian Huayuan Community in Hexibao Town, Yongchang County, Jinchang City, Gansu Province, all...
Bambusa Therapeutics Announces Completion of Series A-2 Financing to Accelerate Next-Generation Bispecific Programs
BOSTON, Nov. 17, 2025 /PRNewswire/ -- Bambusa Therapeutics, Inc. ("Bambusa"), a clinical-stage biotechnology company pioneering next-generation bispecific antibodies for immunology and inflammation (I&I), today announced the completion of its...
Backed by $2 Million, Droplet IV is Set to Launch its Revolutionary Automatic IV-Line Flushing Device in EU & US in 2026
COPENHAGEN, Denmark, June 18, 2025 /PRNewswire/ -- Droplet IV today announced the successful completion of a $2 million funding round to enable launch of its first automatic IV-line flushing device in the EU and US markets. The device addresses a...
ArkBio Announces the Completion of Phase III Clinical Study for AK0901 in the Treatment of Attention Deficit Hyperactivity Disorder (ADHD) in China
SHANGHAI, March 24, 2025 /PRNewswire/ -- Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") today announced the successful completion of the Phase III clinical study of AK0901, a novel drug for the treatment of attention deficit hyperactivity...
BEST Inc. Announces Completion of Going Private Transaction
HANGZHOU, China, March 8, 2025 /PRNewswire/ -- BEST Inc. (NYSE: BEST) ("BEST" or the "Company"), a leading integrated smart supply chain solutions and logistics services provider in China and Southeast Asia, today announced the completion of its...
Akeso Announces Completion of Patient Enrollment in The Phase III Clinical Trial of Cadonilimab for Adjuvant Treatment of High-Risk Recurrent Hepatocellular Carcinoma
HONG KONG, March 6, 2025 /PRNewswire/ -- Akeso, Inc. (9926. HK) ("Akeso" or the "Company") is pleased to announce the completion of patient enrollment for its Phase III registrational clinical trial (COMPASSION-22/AK104-306) evaluating cadonilimab,...
CathWorks Announces the Completion of Enrollment for Landmark ALL-RISE Randomized Controlled Trial
ALL-RISE Study Included Over 1,924 Patients in 59 Sites Across North America, Asia, Europe and the Middle East NEWPORT BEACH, Calif., Jan. 3, 2025 /PRNewswire/ -- CathWorks, a global leader in medical device digital health innovations, announced...